Alzheimer’s & Dementia

Filter Your Results




Investigational Tau Modifier Receives Orphan Drug Status for Progressive Supranuclear Palsy

Wednesday, July 18, 2018—The Food and Drug Administration (FDA) has granted an orphan drug designation to ASN120290 (Asceneuron SA, Lausanne, Switzerland) for the treatment of progressive supranuclear…

Phase 2 Confirmatory Trial of Bryostatin-1 for Alzheimer’s Disease Enrolls First Patient

Monday, July 16, 2018—The first individual has been enrolled into a confirmatory phase 2 clinical trial of bryostatin-1 (Neurotrope, New York, NY) for the treatment of persons with Alzheimer’…

IncobotulinumtoxinA Approved for Treatment of Excessive Drooling

Friday, July 13, 2018—The Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for incobotulinumtoxin A (Xeomin; Merz, Raleigh, NC) for the treatmen…

Can Patients Unique Brain Imaging Fingerprints Direct Clinical Management?

Tuesday, July 10, 2018—Researchers for the Alzheimer's Disease Neuroimaging Initiative from the Montreal Neurology Institute and Hospital (Montreal, Canada) have published results in the journal…

Positive Results for Potential Alzheimer’s Disease Treatment in Phase 2 Trial

Thursday, July 05, 2018—In the first late-stage study to demonstrate potential disease modifying effects for the treatment of persons with Alzheimer’s disease, a monoclonal antibody to amyloid-…

Eisai Inc Launching Center for Genetics-Guided Dementia Discovery Center

Thursday, June 14, 2018—Eisai Inc (Woodcliff Lake, NJ), the U.S. pharmaceutical subsidiary of Eisai Co, Ltd, has announced that the company is committing over $100 million as an initial investment to…

Clinical Trials for Lanabecestat for Treatment of Alzheimer’s Disease Discontinued

Tuesday, June 12, 2018—Phase 3 clinical trials for lanabecestat (Lilly, Indianapolis, IN and AstraZeneca, Wilmington, DE) for the treatment of patients with Alzheimer’s disease (AD) are being …

American Academy of Sleep Medicine Issues Advisory: Insufficient Sleep May Increase Risk for Alzheimer’s Disease

Tuesday, June 05, 2018—The American Academy of Sleep Medicine (AASM) has issued a health advisory warning that insufficient or poor sleep may increase the risk of developing Alzheimer’s diseas…


Contact Info

For advertising rates and opportunities:
Wendy Terry

About Practical Neurology

Launched in 2002, Practical Neurology is a publication uniquely dedicated to presenting current approaches to patient management, synthesis of emerging research and data, and analysis of industry news with a goal to facilitate practical application and improved clinical practice for all neurologists. Our straightforward articles give neurologists tools they can immediately put into practice.